Comparative Pharmacology
Head-to-head clinical analysis: PIROXICAM versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIROXICAM versus ZIPSOR.
PIROXICAM vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
10-20 mg orally once daily; maximum 20 mg/day.
50 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life is 50 hours (range 30-86 hours), allowing once-daily dosing. Prolonged in elderly (up to 80 hours) and in hepatic impairment.
Clinical Note
moderatePiroxicam + Gatifloxacin
"Piroxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePiroxicam + Rosoxacin
"Piroxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePiroxicam + Levofloxacin
"Piroxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePiroxicam + Trovafloxacin
"Piroxicam may increase the neuroexcitatory activities of Trovafloxacin."
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Approximately 60-70% renal (glomerular filtration and tubular secretion) as unchanged drug and metabolites; 30-40% fecal via biliary excretion. Less than 5% as unchanged drug in urine.
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category D/X
Category C
NSAID
NSAID